Walleye Capital LLC Has $1.76 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX

Walleye Capital LLC boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 253.3% in the first quarter, Holdings Channel reports. The firm owned 71,149 shares of the biopharmaceutical company’s stock after acquiring an additional 51,010 shares during the period. Walleye Capital LLC’s holdings in Catalyst Pharmaceuticals were worth $1,762,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. State Street Corp raised its position in shares of Catalyst Pharmaceuticals by 7.8% in the fourth quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock valued at $161,224,000 after purchasing an additional 502,235 shares during the period. Deerfield Management Company L.P. boosted its holdings in shares of Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after buying an additional 2,095,291 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Catalyst Pharmaceuticals by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after buying an additional 433,318 shares during the period. Goldman Sachs Group Inc. grew its stake in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the last quarter. Finally, Morgan Stanley grew its stake in Catalyst Pharmaceuticals by 59.1% in the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after buying an additional 1,089,775 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The company’s fifty day simple moving average is $31.38 and its 200-day simple moving average is $27.27. The company has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. HC Wainwright lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $35.00 to $31.50 in a research report on Thursday, May 28th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).